One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
Recap by typeshit. Post by @fittrwithsquats on Instagram.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
Loading…